

# CITATION REPORT

List of articles citing

## The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data

DOI: 10.17925/EE.2018.14.1.17

European Endocrinology, 2018, 14, 17-23.

**Source:** <https://exaly.com/paper-pdf/87699615/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 157	8.7	60
23	Class effects of SGLT2 inhibitors on cardiorenal outcomes. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 99	8.7	71
22	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 115	8.7	5
21	Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 120	8.7	26
20	Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report. <i>Medicine (United States)</i> , <b>2019</b> , 98, e14150	1.8	8
19	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 92, 170-192	12.7	98
18	Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?. <i>Annals of Pharmacotherapy</i> , <b>2019</b> , 53, 510-522	2.9	5
17	Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 189	8.7	5
16	Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
15	Estimating costs of diabetes complications in people . <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107735	3.2	2
14	Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 556-577	15.2	67
13	Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 87	8.7	15
12	Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 91	8.7	30
11	Glucagon-based therapy: Past, present and future. <i>Peptides</i> , <b>2020</b> , 127, 170296	3.8	8
10	Diabetes mellitus: an important risk factor for peripheral vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2020</b> , 18, 131-137	2.5	7
9	Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis. <i>International Journal of Cardiology</i> , <b>2020</b> , 310, 147-154	3.2	3
8	Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 139	8.7	2

7	Class Effects of SGLT2 Inhibitors on Cardiorenal Outcomes. <b>2021</b> , 279-294		1
6	Diabetes and Lung Disease: A Neglected Relationship. <i>Review of Diabetic Studies</i> , <b>2019</b> , 15, 1-15	3.6	36
5	Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review. <i>Clinical Diabetes</i> , <b>2020</b> , 38, 112-116	2.9	5
4	Oral GLP1 Analog: Where Does the Tide Go?. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , <b>2020</b> , 13, 1179551420984130	4.3	2
3	Risk factors and pharmacological therapy in patients with vascular disease. <b>2022</b> , 11-24		
2	Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. <b>2022</b> , 17, e0274519		0
1	Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival. <b>2023</b> , 128, 1541-1547		1